A college student turned her own cancer scare into a national-award-winning idea for safer chemotherapy.
Quick Take
- Nistha Neupane, a University of Arkansas at Little Rock student, co-created NanoLit, a nanotechnology venture aimed at making chemotherapy less harmful to healthy cells.
- Neupane’s own experience with a benign but cancerous growth pushed her toward targeted cancer research.
- She and classmate Zane Austin won America250’s national “America’s Startup” collegiate competition for the project.
- NanoLit focuses on protecting the heart in breast cancer patients going through chemotherapy.
- Neupane is headed to medical school this fall after years of lab work and a research trip to Nepal.
A Health Scare That Changed Her Focus
Neupane found out she had a growth that was cancerous but benign, meaning it had not spread through her body. That diagnosis gave her a firsthand look at how frightening cancer treatment can feel. It also pushed her to ask a sharper question. Could cancer drugs target tumors without tearing through healthy tissue along the way? That question became the seed for years of research.
Neupane studies clinical biology and chemistry at UA Little Rock as a Donaghey Scholar. She spent two years working under chemistry professor Dr. Noureen Siraj, studying gold nanoparticles for cancer therapy. The research explored how the shape of these tiny particles changes how well they deliver drugs to tumors. She earned a Student Undergraduate Research Fellowship grant two years running to fund that work, a sign her ideas carried weight with state science reviewers.
From Lab Bench To National Stage
That research became the foundation for NanoLit, a venture Neupane built with fellow student Zane Austin. The university describes NanoLit as a project designed to fix one of chemotherapy’s biggest problems: it attacks healthy cells along with cancerous ones. Their specific target is the heart. The pair built therapies meant to protect heart tissue in breast cancer patients while chemotherapy drugs still do their job.
The idea won over judges at America250, a national competition tied to the United States’ upcoming 250th anniversary celebration. Neupane and Austin took first place in the “America’s Startup” collegiate track, beating out teams from across the country. For a state university chemistry project built in an undergraduate lab, that national recognition marks a real validation of years of unglamorous bench work.
Why Targeted Delivery Matters In Cancer Care
Neupane’s instinct lines up with where cancer research has been heading for two decades. Drug delivery systems that aim treatment more precisely at tumors have shown real promise in clinical studies for cutting down toxicity in healthy tissue. Chemotherapy has long been a blunt tool, poisoning fast-growing cells wherever they are, cancerous or not. Anything that narrows that blast radius is worth serious attention, and patients have waited a long time for it.
That said, the nanomedicine field has learned patience the hard way. Plenty of promising lab discoveries never make it to pharmacy shelves, and experts in the field describe a “crossroads” moment where early hype has met the slower reality of clinical trials and regulatory approval. None of that diminishes what Neupane built. It simply means the road from a winning pitch competition to a treatment in a hospital room is long, and every serious researcher in this space knows it.
A Pattern Of Hands-On Learning
Neupane’s path to NanoLit did not start with a business plan. It started with advocacy and patient care. She spent six weeks interning at a hospital in Kathmandu, Nepal, as part of a medical study abroad program, getting direct exposure to patient treatment in a resource-limited setting. She also won UA Little Rock’s Whitbeck Award, recognized for work connecting her nanoparticle research to broader medical advocacy and for presenting findings at national chemistry conferences.
Neupane is now headed to the University of Texas at Tyler School of Medicine as an incoming first-year medical student. She leaves undergraduate research with a national startup win, two competitive state grants, and a hospital internship overseas already behind her. Whether NanoLit eventually reaches patients will depend on years of trials ahead. But the story of a student converting her own diagnosis into a tool meant to spare other families the worst of chemotherapy’s side effects is already a finished chapter worth telling.
Sources:
mindbodygreen.com, ualr.edu, america250.org, linkedin.com, frontiersin.org, dspace.library.uu.nl
